Lumerax 40mg/240mg Tablet is a fixed-dose combination antimalarial medication containing Artemether 40mg and Lumefantrine 240mg. It is indicated for the treatment of uncomplicated Plasmodium falciparum malaria. Artemether, a rapid-acting artemisinin derivative, exerts potent schizonticidal activity against the asexual erythrocytic stages of malaria parasites, leading to a swift reduction in parasitemia and symptomatic relief. Lumefantrine, a longer-acting antimalarial agent, complements Artemether by eliminating residual parasites, thereby reducing the risk of recrudescence. The combination therapy enhances efficacy and helps prevent the development of drug resistance. Lumerax is administered orally, typically as a six-dose regimen over three days, with doses taken at 0, 8, 24, 36, 48, and 60 hours. It is recommended to be taken with food to improve absorption. Common adverse effects may include headache, dizziness, fatigue, and gastrointestinal disturbances such as nausea or abdominal pain. Caution is advised in patients with known hypersensitivity to artemisinins or lumefantrine and in those with cardiac conduction abnormalities, as QT prolongation has been reported. Lumerax should be used under medical supervision, with adherence to the full treatment course to ensure therapeutic success and minimize resistance development.